The high expression rate of gpC1 in BCA suggests this blood group precursor antigen may be a BCA biomarker, and the strikingly high percentage of gpC1 positive CTCs in the advanced stage of triple-negative BCA indicate gpC1 is potentially associated with aggressive tumor behaviour. The gene discussed is GPC1; the disease is neoplasm.